Viral Vectors & Vaccines
Oncolytic viruses | Viral vectors for Cell and Gene Therapies | Infectious diseases
We are an end-to-end viral vector CDMO with a track record in developing and manufacturing a wide variety of viral vector types. We have built processes from both adherent and suspension cell lines and offer upstream processing from small scale up to 1,000 L SUB scale. Our capabilities extend to viral vectors such as adenovirus, lentivirus, adeno-associated viruses (AAV), and other viruses.
Providing you with a wide variety of services for viral vectors
HALIX manufactures viral vectors, vaccines, oncolytic viruses and other viral products in our BSL2 cleanrooms. Our virus production area comprises several EU GMP class C cleanrooms for cell culturing, upstream and downstream processing, and Class B cleanrooms for fill and finish. Our processes run completely on single use technology and our technology platform and in-depth know-how ensures smooth scale up from lab to industrial scale, while our transparent and agile project management ensures minimum risks.
Diverse range of cell lines and viruses
experience with HEK293, VERO, SF9, PER.C6, HeLa
Track record for different indications
COVID-19, HIV, Zika, Chikungunya, Influenza, Cancer
Complete manufacturing cycle in house
including USP (bioreactors, cell factories), DSP (chromatography, filtration, TFF), and DP (formulation aseptic fill and finish in vials, lyophilization)
Comprehensive GMP experience
wide range of services including MVS/WVS, MCB/WCB, TOX and Tech batches, placebo, clinical and commercial supply
Case study: viral vaccine
Rapid scale up to GMP commercial scale for the development and manufacture of COVID-19 vaccine based on adenovirus vector.
Q4 2019
New 6,900 m2 facility opens
Q1 2020
Signed agreement for COVID vaccine
Q3 2020
First clinical GMP batch delivered
Q4 2020
Parallel production up to 1,000 L batch per week
“We achieved on-time delivery of a completely novel vaccine while starting from a brand new empty facility and having to assemble all of the necessary equipment, processes, and qualifications for commercial production along the way. This success was only possible through our tight collaboration with AstraZeneca and our team’s internal work with military precision.“
Dennis Verbart, Senior Director Science and Technology at HALIX
How will partner with you
Developing and manufacturing virus products comes with its own unique set of difficulties and risks. Whether you are a small biotech or a large pharma, open communication between your organization and the viral vector CDMO partner is key to achieving success.
At HALIX we commit to full transparency and alignment with you every step of the way. Our project management approach is built on a foundation of open communication and agility, with short and direct communication channels, allowing us to quickly adapt and respond to any obstacles that may arise.
The HALIX full service offering for virus product manufacturing
As an end-to-end viral vector CDMO, we work closely with our partners to create tailor-made process and analytical development at a scale required for individual projects, produce drug substance and drug product with a flexible approach for seamless customer process transfer and perform in-house testing ensuring all products meet strict quality standards.
We support your product development with scalable and robust small scale production, analytical development, and upscaling services.
We have a solid track record in the production of viral vectors and viral vaccines, from tech and TOX batches to commercial scale, under cGMP.